Global Antibiotic Research and Development Partnership (GARDP)
GARDP is a not-for-profit global health organization dedicated to developing and making accessible antibiotic treatments to combat drug-resistant infections. It collaborates with public and private partners worldwide to address the global threat of antimicrobial resistance through research, development, and access initiatives. Recently, GARDP developed a new antibiotic for gonorrhea, a disease increasingly resistant to existing treatments, highlighting its commitment to innovative solutions for antibiotic resistance.
Industries
Nr. of Employees
small (1-50)
Global Antibiotic Research and Development Partnership (GARDP)
Products
Phase III development program for a novel oral antibiotic for gonorrhoea
Multicountry Phase III development programme and regulatory submission support for a new oral therapy intended to treat uncomplicated gonorrhoea.
Paediatric development of a beta‑lactam/beta‑lactamase inhibitor combination
Paediatric development programme to extend an antibiotic combination for use in children, including formulation and dosing work to support paediatric indications.
NeoSep1: Clinical trial programme for neonatal sepsis regimen evaluation
An interventional trial programme testing combinations of existing antibiotics to identify optimal empiric regimens for hospitalised newborns with sepsis.
Antibiotic access sublicensing and technology transfer projects
Projects to sublicense rights and transfer manufacturing technology for essential antibiotics to broaden supply in targeted regions.
Open-access knowledge platform and webinar series
An online hub offering webinars, articles and recorded content to connect the antimicrobial community and disseminate research and guidance; includes live and recorded webinars and published open-access analyses.
Phase III development program for a novel oral antibiotic for gonorrhoea
Multicountry Phase III development programme and regulatory submission support for a new oral therapy intended to treat uncomplicated gonorrhoea.
Paediatric development of a beta‑lactam/beta‑lactamase inhibitor combination
Paediatric development programme to extend an antibiotic combination for use in children, including formulation and dosing work to support paediatric indications.
NeoSep1: Clinical trial programme for neonatal sepsis regimen evaluation
An interventional trial programme testing combinations of existing antibiotics to identify optimal empiric regimens for hospitalised newborns with sepsis.
Antibiotic access sublicensing and technology transfer projects
Projects to sublicense rights and transfer manufacturing technology for essential antibiotics to broaden supply in targeted regions.
Open-access knowledge platform and webinar series
An online hub offering webinars, articles and recorded content to connect the antimicrobial community and disseminate research and guidance; includes live and recorded webinars and published open-access analyses.
Services
End-to-end management of multicountry clinical trials for antibiotic candidates, including site activation, recruitment and oversight.
Design and delivery of large observational studies to characterise treatment gaps and resistance patterns, used to inform interventional trials.
Design and implementation of a consortium-based access facility to procure and deploy essential and new antibiotics responsibly in LMICs, including stewardship and country engagement.
Negotiation and coordination of sublicenses and technology transfer agreements to enable regional manufacture and supply of antibiotics, and coordination with manufacturing partners to secure production capacity.
Establishing public–private partnerships and issuing requests for proposals or licensing opportunities to accelerate R&D and access.
Provision of open-access webinars, articles, recorded content and newsletters to convene experts, disseminate guidance and share research findings; includes external media engagement and use of content distribution platforms.
End-to-end management of multicountry clinical trials for antibiotic candidates, including site activation, recruitment and oversight.
Design and delivery of large observational studies to characterise treatment gaps and resistance patterns, used to inform interventional trials.
Design and implementation of a consortium-based access facility to procure and deploy essential and new antibiotics responsibly in LMICs, including stewardship and country engagement.
Negotiation and coordination of sublicenses and technology transfer agreements to enable regional manufacture and supply of antibiotics, and coordination with manufacturing partners to secure production capacity.
Establishing public–private partnerships and issuing requests for proposals or licensing opportunities to accelerate R&D and access.
Provision of open-access webinars, articles, recorded content and newsletters to convene experts, disseminate guidance and share research findings; includes external media engagement and use of content distribution platforms.
Expertise Areas
- Clinical trial management for antimicrobials
- Neonatal sepsis clinical research
- Paediatric antibiotic development and dose optimisation
- Antibacterial discovery and preclinical screening
Key Technologies
- Multicentre clinical trial platforms
- Observational study design and analytics
- Compound library screening assays
- Preclinical antibacterial activity assays
News & Updates
Summary of GARDP's achievements and milestones in 2024, including clinical trials, partnerships, and funding.
Discussion on the global crisis of antibiotic resistance and GARDP's efforts to develop new treatments and expand access.
Development of Zoliflodacin in Phase III trials
Progress in clinical trials for a new treatment for gonorrhea, with potential FDA approval.
Partnerships for access to cefiderocol and other antibiotics
Collaborations with pharmaceutical companies and governments to expand access.
Significant funding commitments from governments and organizations
Support from Germany, UK, Japan, Monaco, and others to fund GARDP's initiatives.
GARDP developed a new antibiotic to combat rising resistance in gonorrhea, a WHO priority pathogen.
Summary of GARDP's achievements and milestones in 2024, including clinical trials, partnerships, and funding.
Discussion on the global crisis of antibiotic resistance and GARDP's efforts to develop new treatments and expand access.
Development of Zoliflodacin in Phase III trials
Progress in clinical trials for a new treatment for gonorrhea, with potential FDA approval.
Partnerships for access to cefiderocol and other antibiotics
Collaborations with pharmaceutical companies and governments to expand access.
Significant funding commitments from governments and organizations
Support from Germany, UK, Japan, Monaco, and others to fund GARDP's initiatives.
GARDP developed a new antibiotic to combat rising resistance in gonorrhea, a WHO priority pathogen.